hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as t Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D. 20231, on the date sharp below. January 3, 2003 Ву:

PATENT Docket No. GC626-3

	IN THE UNITED STATES	PATENT AND TRADEMARK OF	FICE	
In re A	Application of)		
Estell	et al.) Group Art Unit: 1645		
Serial	No. 09/932,279) Examiner: Not Assigned		
Filed:	August 17, 2001)))	RECEIVED	
FOI.	Mass Spectrometric Analysis of Biopolymers)	JAN 0 7 2003	
	Information	Disclosure Statement	TECH CENTER 1600/2900	
	nissioner for Patents ington, DC 20231			
Sir:				
Applic	ants submit herewith patents, public	cations or other information (listed	on the attached	
Form	PTO-1449 and attached thereto) of	which they are aware, that they be	elieve may be	
mater	ial to the examination of this applicat	tion and in respect of which there	may be a duty to	
disclo	se in accordance with 37 CFR §1.56	3 .		
This I	nformation Disclosure Statement: (a) accompanies the ne §1.97(a).	ew patent application submitted he	erewith. 37 CFR	
	(b) is filed within three r three months after the date as set forth in 37 CFR §1.4	months after the filing date of the of entry into the national stage of 91.	application or within f a PCT application	
	(c)⊠ as far as is known to first Office Action on the me	o the undersigned, is filed before erits.	the mailing date of a	
		t Office Action and more than thre		

	rejecti either specif Depos Inform	known to the undersigned, prior to the mailing date of either a final on or a notice of allowance, whichever occurs first, and is accompanied by the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as ied in 37 CFR §1.97(e), as checked below. Authorization to charge sit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this nation Disclosure Statement is provided in the Transmittal Letter submitted ith in duplicate.
	allowa Transi No. 07 as spe consi	is filed after the mailing date of either a final rejection or a notice of ince, whichever occurred first, and is accompanied by authorization (in the mittal Letter submitted herewith in duplicate) to charge Deposit Account 7-1048 the fee (\$180.00) set forth in 37 CFR §1.17(I)(1) and a certification ecified in 37 CFR §1.97(e), as checked below. This document is to be dered as a petition requesting consideration of the Supplemental nation Disclosure Statement.
[If either of b	oxes (d) or (e) is checked above, the following "certification" under 37 CFR
§1.97(e) may	need t	o be completed.] The undersigned certifies that:
	counte	Each item of information contained in the Information Disclosure nent was cited in a communication mailed from a foreign patent office in a erpart foreign application not more than three months prior to the filing of formation Disclosure Statement.
	foreigi reasoi	No item of information contained in this Information Disclosure Statement ted in a communication mailed from a foreign patent office in a counterpart application or, to the knowledge of the undersigned after making hable inquiry, was known to any individual designated in 37 CFR §1.56(c) than three months prior to the filing of this Information Disclosure ment.
, filed _	_ with	on Form PTO-1449 is supplied: PCT International Search Report for attached patents and publications. Hone only those listed below:
PTO-1449 are	e not su ation, S	ublication(s) which are marked with an asterisk (*) on the attached Form applied because they were previously cited by or submitted to the Office in erial No. 09,932,369, filed August 17, 2001, and relied upon in this elier filing date under 35 USC 120.
A concise exp	olanatio	n of relevance of the items listed on PTO-1449 is:
	\boxtimes	not given
		given for each listed item

Serial No. 09/932,279 Page 3

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

reg. no 32,247

Date: January 3, 2002

H. Thomas Anderton, Jr. Registration No. 40,895

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650 846-7544 Fax: 650 845-6504

	INFORM	IATION DISCLOSURE CITATION
Attorney Docket No.: GC626-	3 QE JCO,	Serial No.: 09/932,279
Applicant: Estell et al.	O SOUTH	•
Filing Date: August 17, 2001	IAL FALL	Group: 1645
Page 1 of 2	Religi	Date of this Submission: January 3, 2002
	C.0100	

DECEIVED

	OTHER DOC	CUMENTS	RECEIVED			
Examiner's			JAN 0 7 2003			
Initials	Author, Title, Date, Pertinent Pages, etc.		3AN 0 1 2003			
	* Allen, G., "Sequencing of Proteins and Peptides,"	2 nd edn. Elsevier, Amsterdam Book	TECH CENTER 1600/29			
	*Altschul et al., "Basic Local Alignment Search Too	l," J. Mol. Biol., V. 215, 1990, pp. 403-4	10.			
	*Bairoch el et al., "The SWISS-PROT protein seque Res., Vol. 28, pp. 45-48, 2000.	ence database and its supplement TrEM	1BL in 2000," Nucl. Acids			
•	*Burks et al., "GeneBank: Current Status and Future Directions," Methods in Enzymology, V. 138, pp. 3-22 (1990).					
	*Chowdhury et al., "Examination of Recombinant Truncated Mature Human Fibroblast Collagenase by Mass Spectrometry: Identification of Difference with the Published Sequence and Determination of Stable Isotope Incorporation," Rapid Commun. in Mass Spectom., Vol. 9, pp. 563-569, 1995.					
	*Corthals et al., "Identification of Proteins by Mass Spectrometry," Ed. Rabilloud, T. Springer, New York, pp. 197-231					
	*Christianson et al., "Peptide Mapping of Subtillisins as a Practical tool for Locating Protein Sequence Errors during Extensive Protein Engineering Projects," Anal. Bioch. 1994, Vol. 223, pp. 119-129.					
	* Deutscher MP, "Guide to Protein purification," Ac	ademic Press, New York Book				
	*George et al., "PIR-International Protein Sequence	Database", Methods in Enzymology,	/. 266, pp. 41-59 (1996).			
	*Goddette et al., "The Crystal Structure of the Bacillus lentus Alkaline Protease, Subtilisin BL, at 1 .4 A Resolution", J. Mol. Biol, V. 228, pp. 580-595 (1992).					
	*Goeddel et al., "Synthesis of Human Fibroblast Into	erferon by E. coli," Nucl. Acids Res., Vo	ol. 8, pp. 4057-4074, 1980.			
	*Guermant et al., "Under Proper Control, Oxidation of Proteins with Known Chemical Structure Provides an Accurate and Absolute Method for the Determination of Their Molar Concentration", Anal. Biochem. V. 277, pp. 46-57 (2000).					
	*Gygi et al., "Quantitative analysis of complex protein mixtures using isotope-coded affinity tags," Nature Biotech. V. 17, pp. 994-999 (1999).					
	* Hale & Marham, The Harper Collins Dictionary of Biology, Harper Perennial, NY (1991) Book					
	* Hancock ES, "New Methods in Peptide Mapping for the Characterization of Proteins", CRC Press, Boca Raton					
	*Hsia et al., "Active-Site Titration of Serine Proteases Using a Fluoride Ion Selective Electrode and Sulfonyl Fluor Inhibitors," Analytical Biochem., V. 242, pp. 221-227 (1996).					
	* Janson et al., "Protein Purification," 2nd edn., Wiley-Liss, New York Book					
	* Kellner et al., "Microcharacterization of Proteins", 2nd edn., Wiley-VCH, Weinheim Book					
	*Khan et al., "EMBL Data Library", Methods in Enzymology, V. 183, pp. 23-31 (1990).					
	Karlin et al., "Application and Statistics for Multiple High-Scoring Segments in Molecular Sequence," Proc. Natl. Ac Sci. USA, V. 90, pp. 5873-5877 (1993).					
	*Karlin et al., "Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes," Proc. Natl. Acad. Sci. USA, V. 87, pp. 2264-2268 (1990).					
Examiner		Date Considered				

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket No.: GC626-3	Serial No.: 09/932,279	
Applicant: Estell et al.		RECEIVE
Filing Date: August 17, 2001	Group : 1645	
Page 2 of 2	Date of this Submission: January 3, 2002	JAN 0 7 2003

	OTHER DOCUMENTS TECH CENTER 1600			
Examiner's Initials	Author Title Date Portinent Person etc			
Initials	Author, Title, Date, Pertinent Pages, etc.			
	*Kunst, et al., "The complete genome sequence of the Gram-positive bacterium Bacilus subtilis," Nature, Vol. 390, pp. 249-256, 1997.			
	*Lahm, et al., "Mass spectrometry: A tool for the identification of proteins separated by gels," Electrophoresis, Vol. 21, pp. 6591-6596, 1999.			
	* Matsudaira, P., "A Practical Guide to Protein and Peptide Purification for Microsequencing," 2 nd edn, Academic Press, San Diego Book			
	*Oda, et al., "Accurate quantitation of protein expression and site-specific phosphorylation," Proc. Natl. Acad. Sci. USA, V. 96, pp. 2264-2268 (1990).			
	*Pace, et al., "How to measure and predict the molar absorption coefficient of a protein," Protein Science, V. 4, pp. 2411-2423 (1995).			
	* Scopes R., "Protein Purification," 3 rd end. Springer-Verlag, New York Book			
. "	* Singleton et al., Dictionary of Microbiology and Molecular Biology, 2D ED., John Wiley and Sons, New York (1994) Book			
	*Stocklin, et al., "A Stale Isotope Dilution Assay for the In Vivo Determination of Insulin Levels in Humans by Mass Spectrometry," Diabetes, V. 46, pp. 44-50 (1995).			
	 			
Examiner	Date Considered			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

PTO-1449

INFORMATION DISCLOSURE CITATION

INFORMATION DISCLOSURE STATION				
Attorney Docket No.: GC626-3	Serial No.: 09/932,279			
Applicant: Estell et al.				
Filing Date: August 17, 2001	Group: 1645			
Page 1 of 1	Date of this Submission: January 3, 2002			
	DEICH DATENT DOCUMENTS			

Examiner's	Document	TEM 8 IM			Sub-	Translation
Initials	Number	Date	Country	Class	Class	Yes/No
	W0 00 20357 A	04/13/00	PCT			
	W0 97 37953 A	10/16/97	PCT			

	OTHER DOCUMENTS			
Examiner's				
Initials	Author, Title, Date, Pertinent Pages, etc.			
	Chen et al., "Isotope Edited Product Ion Assignment by alpha-N Labeling of peptides with 'H3(50%)!2, 4-Dinitrofluorobenzene," J. of the American Society for Mass Spectrometry, Elsevier Science, Inc., New York, NY, US, V. 10 (5), May 1999, pp. 448-452 Abstract			
		RECEIVED		
	JAN 0 7 2003			
	TECH CENTER 1600/290			
Examiner		Date Considered		
Examiner: In	nitial if reference considered, whether or not citation formance and not	is in conformance with MPEP 609; draw line through citation		
considered.	Include copy of this form with next communication to	to applicant. PTO-1449		